CureDuchenne provided early and significant funding to Capricor Therapeutics for their Duchenne program, and we are pleased to share their latest updates. One-year results from their HOPE-2 open label extension […]
Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid […]
PTC_June2022Download
Significant decreases in key biomarkers of muscle damage.
CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
We’re thrilled to announce that researchers at Nationwide Children’s Hospital have documented the first-ever creation of full-length dystrophin in a human as a response to gene therapy. CureDuchenne has contributed […]
Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]
Pfizer’s Letter to the Duchenne Community We are pleased to share the good news that several regulatory authorities have approved the re-start of our Phase 3 ambulatory trial (CIFFREO) for […]
We are pleased to share that Edgewise Therapeutics is sponsoring a natural history study in Becker muscular dystrophy, to better understand the course of disease and define endpoints to be […]